Biochemistry & Pharmacology: Open Access
Open Access

Atherogenic Dyslipidemia Research Articles

Atherogenic dyslipidemia (AD) refers to elevated levels of triglycerides (TG) and small-dense low-density lipoprotein and low levels of high-density lipoprotein cholesterol (HDL-C).In AD, there's impaired insulin signalling which increases lipolysis i.e. conversion of TG into free fatty acids (FFA) in adipocytes. These FFA are transported to liver and muscles via blood.[6] Majority of FFA are re-esterified to TG which along side posttranslational stabilization of ApoB enhances the assembly and secretion of VLDL particles. The VLDL production is further augmented by elevated plasma glucose concentrations. Two sorts of VLDL are synthesized by liver- VLDL-1, the massive TG-rich VLDL, and VLDL-2, the smaller TG-poor VLDL.[7] Predominantly, overproduction of VLDL-1 within the liver is seen in patients with AD, insulin resistance and sort 2 diabetes; determining atherogenicity of plasma lipoproteins.